Literature DB >> 22836122

Links between genome integrity and BRCA1 tumor suppression.

Mischa L Li1, Roger A Greenberg.   

Abstract

BRCA1 and BRCA2 are two major breast and ovarian cancer susceptibility genes. BRCA1 was the first discovered and has been a focus of research for these cancers. BRCA1 mediates tumor suppression in part through pleiotropic interactions with a network of DNA repair proteins on chromatin. BRCA1 mutations cause homologous recombination (HR)-mediated DNA repair deficiency, genomic instability, and DNA-damaging agent hypersensitivity. Although BRCA1 and BRCA2 have some shared functions in cancer predisposition and therapy response, there are also key differences indicating divergent roles for each protein. This review summarizes and highlights recent insights into the molecular events responsible for BRCA1 tumor suppression, emphasizing the DNA repair function of BRCA1 as a nexus between its roles in cancer development and therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836122      PMCID: PMC3459146          DOI: 10.1016/j.tibs.2012.06.007

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  80 in total

1.  BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Authors:  Reena Shakya; Latarsha J Reid; Colleen R Reczek; Francesca Cole; Dieter Egli; Chyuan-Sheng Lin; Dirk G deRooij; Steffen Hirsch; Kandasamy Ravi; James B Hicks; Matthias Szabolcs; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

2.  BRCA1 is required for postreplication repair after UV-induced DNA damage.

Authors:  Shailja Pathania; Jenna Nguyen; Sarah J Hill; Ralph Scully; Guillaume O Adelmant; Jarrod A Marto; Jean Feunteun; David M Livingston
Journal:  Mol Cell       Date:  2011-09-29       Impact factor: 17.970

3.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.

Authors:  Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

4.  Cancer predisposing BARD1 mutations in breast-ovarian cancer families.

Authors:  Magdalena Ratajska; Ewelina Antoszewska; Anna Piskorz; Izabela Brozek; Åke Borg; Hanna Kusmierek; Wojciech Biernat; Janusz Limon
Journal:  Breast Cancer Res Treat       Date:  2011-02-23       Impact factor: 4.872

5.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

Authors:  Barbara Norquist; Kaitlyn A Wurz; Christopher C Pennil; Rochelle Garcia; Jenny Gross; Wataru Sakai; Beth Y Karlan; Toshiyasu Taniguchi; Elizabeth M Swisher
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

Review 6.  BRCA1 and BRCA2: different roles in a common pathway of genome protection.

Authors:  Rohini Roy; Jarin Chun; Simon N Powell
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

7.  Regulation of DNA end joining, resection, and immunoglobulin class switch recombination by 53BP1.

Authors:  Anne Bothmer; Davide F Robbiani; Michela Di Virgilio; Samuel F Bunting; Isaac A Klein; Niklas Feldhahn; Jacqueline Barlow; Hua-Tang Chen; David Bosque; Elsa Callen; André Nussenzweig; Michel C Nussenzweig
Journal:  Mol Cell       Date:  2011-05-06       Impact factor: 17.970

Review 8.  Secondary mutations of BRCA1/2 and drug resistance.

Authors:  Kiranjit K Dhillon; Elizabeth M Swisher; Toshiyasu Taniguchi
Journal:  Cancer Sci       Date:  2011-01-30       Impact factor: 6.716

9.  BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Authors:  Rinske Drost; Peter Bouwman; Sven Rottenberg; Ute Boon; Eva Schut; Sjoerd Klarenbeek; Christiaan Klijn; Ingrid van der Heijden; Hanneke van der Gulden; Ellen Wientjens; Mark Pieterse; Aurelie Catteau; Pete Green; Ellen Solomon; Joanna R Morris; Jos Jonkers
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

10.  BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.

Authors:  Quan Zhu; Gerald M Pao; Alexis M Huynh; Hoonkyo Suh; Nina Tonnu; Petra M Nederlof; Fred H Gage; Inder M Verma
Journal:  Nature       Date:  2011-09-07       Impact factor: 49.962

View more
  51 in total

1.  USP11 Is a Negative Regulator to γH2AX Ubiquitylation by RNF8/RNF168.

Authors:  Miao Yu; Kun Liu; Zebin Mao; Jianyuan Luo; Wei Gu; Wenhui Zhao
Journal:  J Biol Chem       Date:  2015-10-27       Impact factor: 5.157

Review 2.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

3.  Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.

Authors:  Yongxian Ma; York Tomita; Anju Preet; Robert Clarke; Erikah Englund; Scott Grindrod; Shyam Nathan; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2014-12

Review 4.  The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression.

Authors:  Suhwan Chang; Shyam K Sharan
Journal:  Transcription       Date:  2012-11-06

5.  BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.

Authors:  Shyam Nathan; Yongxian Ma; York A Tomita; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Breast Cancer Res Treat       Date:  2017-08-14       Impact factor: 4.872

6.  ASF1a Promotes Non-homologous End Joining Repair by Facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks.

Authors:  Kyung Yong Lee; Jun-Sub Im; Etsuko Shibata; Anindya Dutta
Journal:  Mol Cell       Date:  2017-09-21       Impact factor: 17.970

7.  The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.

Authors:  Antonio Marzio; Joseph Puccini; Youngho Kwon; Natalia K Maverakis; Arnaldo Arbini; Patrick Sung; Dafna Bar-Sagi; Michele Pagano
Journal:  Mol Cell       Date:  2018-12-13       Impact factor: 17.970

8.  BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.

Authors:  Dali Zong; Salomé Adam; Yifan Wang; Hiroyuki Sasanuma; Elsa Callén; Matilde Murga; Amanda Day; Michael J Kruhlak; Nancy Wong; Meagan Munro; Arnab Ray Chaudhuri; Baktiar Karim; Bing Xia; Shunichi Takeda; Neil Johnson; Daniel Durocher; André Nussenzweig
Journal:  Mol Cell       Date:  2019-01-28       Impact factor: 17.970

9.  BRCA1 pathway function in basal-like breast cancer cells.

Authors:  Sarah J Hill; Allison P Clark; Daniel P Silver; David M Livingston
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

10.  Luring BRCA1 to the scene of the crime.

Authors:  Richard Baer
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.